Live data from Hacker News

The APA Meeting: A Photo-Essay

slatestarcodex.com

31–35 of 35 posts

Re: The APA Meeting: A Photo-Essay

#31
post #30
post #14

Earlier quoted context omitted.

I loved this post (basically a balanced criticism of psychiatry by a psychiatrist), and I think it makes a great HN submission .

I actually think it's worth taking the time to break down what makes something a good or bad HN submission. Some elements present in this piece that, when combined , seem to drive the worst kinds of HN threads: * A spicy take * A subject almost no likely commenters have any expertise on * A subject that lots of likely commenters have their own spicy takes on * Invocation of "wokeness" * Perennial HN punching bag targ…

I agree, but the benefit/interest in HN isn't just in comment threads... for me, it's my primary source of interesting relevant information (e.g. as opposed to news sites, which are mainly interesting but irrelevant (in the grand scheme of things) information)... and sometimes, that's in comments, other times it's in the articles posted.

Re: The APA Meeting: A Photo-Essay

#32
Last I heard (three or four years ago), the APA was suffering from a fall-off in pharma advertising. If that is the case, and it hasn't rebounded, just think what the advertising must have been fifteen years ago.

Re: The APA Meeting: A Photo-Essay

#33

There's illumination here for those of us who've been prescribed shockingly expensive drugs with generic near-equivalents going for 1/40th the price (as I have): >I asked the Lucemyra® representative why I might prescribe Lucemyra® instead of clonidine for opiate withdrawal. She said it was because Lucemyra® is FDA-approved for this indication, and clonidine isn’t. This is the same old story as Rozerem® vs. melatonin…

My doctor prescribes ketamine lozenges. They are quite cheap, safe, and possibly as effective as IV (more research needed here). He said his insurance didn't change at all. What the world needs is psychiatrists who are willing to take the _risk_ of prescribing a safe drug with a long history in medicine.

Yes, the long-term effects of taking ketamine frequently are not well understood. In my opinion a patient with TRD should be allowed to take this risk provided that they have tried several other drugs.

Re: The APA Meeting: A Photo-Essay

#34

There's illumination here for those of us who've been prescribed shockingly expensive drugs with generic near-equivalents going for 1/40th the price (as I have): >I asked the Lucemyra® representative why I might prescribe Lucemyra® instead of clonidine for opiate withdrawal. She said it was because Lucemyra® is FDA-approved for this indication, and clonidine isn’t. This is the same old story as Rozerem® vs. melatonin…

There's also illumination for people who are interested in the debate on whether or not one should research medical issues on the internet yourself, or "trust your doctor, they're a professional".

There are externalities for experimentation which include bankrupting the health system. Imagine if everyone only ate red meat. Bowel cancer would soar.

Re: The APA Meeting: A Photo-Essay

#35
post #10

It's kind of horrifying to consider that advertising has a statistically significant chance of influencing a psychiatrist away from prescribing based on what best suits the indication.

Strong statistical significance. When I was in med school (UCLA 1970-74) everybody took aspirin and/or Tylenol. Now, I'm the only person I know of who still takes those two drugs rather than the zillions of newer, more expensive pain relievers. Why? Because none of the drug company-sponsored studies concluding that their new drug was better than my old standbys were convincing to me. As an experienced scientist who co-authored a number of investigational drug studies, I know whereof I speak. References:https://scholar.google.com/citations?user=5DdrMc8AAAAJ&hl=en
Post reply on HN